COMMUNIQUÉS West-GlobeNewswire

Trillium Therapeutics Reports Annual Financial and Operating Results
11/03/2019
Positive data from the intratumoral trial of TTI-621, a CD47 immune checkpoint inhibitor, presented at the 2018 EORTC CLTF and ASH 2018 meetings Encouraging signals of activity and tolerability data from the intravenous [...]
ERYTECH Provides Business Update and Reports Financial Results for Full Year 2018
11/03/2019
Conference call and webcast on Tuesday, March 12 th at 1:30 pm CET/8:30 am EDT TRYbeCA1, a pivotal Phase 3 trial for eryaspase in second line pancreatic cancer, now actively enrolling patients TRYbeCA2, a proof of [...]
ERYTECH publie ses résultats financiers et fait le point sur ses activités de l’exercice 2018
11/03/2019
Conférence téléphonique et webcast mardi 12 mars à 13h30 (heure de Paris) Recrutement en cours dans l’étude TRYbeCA1 de phase 3 avec eryaspase dans le traitement en seconde ligne du cancer du pancréas Début du [...]
Zosano Pharma Announces Presentation and Participation at the 31st Annual Roth Conference
11/03/2019
FREMONT, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its chairman, president and chief executive officer, John [...]
Radius Health to Present at Cowen 39th Annual Healthcare Conference
11/03/2019
WALTHAM, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Høiland, President and CEO of the Company, will present a corporate update at the Cowen 39 th Annual [...]
Novavax to Host Conference Call to Discuss Fourth Quarter and Year-End 2018 Financial Results on March 18, 2019
11/03/2019
GAITHERSBURG, Md., March 11, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its fourth quarter 2018 financial and operating results prior to U.S. financial markets opening on Monday [...]
Oxford Immunotec Reports Fourth Quarter and Full Year 2018 Financial Results
11/03/2019
OXFORD, United Kingdom and MARLBOROUGH, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the "Company"), a global, high-growth diagnostics company, today announced fourth quarter and [...]
ShockWave Announces Closing of its Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
11/03/2019
SANTA CLARA, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- ShockWave Medical, Inc. (“ShockWave”) (Nasdaq: SWAV), today announced the closing of its initial public offering of 6,555,000 shares of its common stock at an [...]
Résultats 2018 du HOOPP : tenir la promesse de pension offerte à nos membres
11/03/2019
La situation de capitalisation est de 121 % et l'actif net a augmenté à 79 milliards de dollars TORONTO, 11 mars 2019 (GLOBE NEWSWIRE) -- Le Healthcare of Ontario Pension Plan (HOOPP) a annoncé aujourd’hui que son actif [...]
ChemoCentryx Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights
11/03/2019
-- Strong Progress Across Company’s Orphan Disease Franchise of Novel Renal and Dermal Therapeutics -- -- Pivotal top-line data expected from ADVOCATE Phase III trial of C5a receptor inhibitor avacopan in ANCA- [...]
Soleno Therapeutics to Participate in Two Upcoming Investor Conferences
11/03/2019
REDWOOD CITY, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, [...]
MRI Interventions Reports 36% Increase in Fourth Quarter Revenue and Record Quarterly ClearPoint® Cases
11/03/2019
Fourth Quarter Cash Burn from Operations Reduced to $600,000 IRVINE, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB: MRIC) (the “Company”) today announced financial results for its fourth [...]
CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
11/03/2019
NEWARK, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients [...]
Zafgen Reports Fourth Quarter and Full Year 2018 Operating and Financial Results and Provides Key Program and Business Updates
11/03/2019
Recently announced positive results for second cohort of Phase 2 clinical trial of ZGN-1061 Updates on progress preparing for FDA Type A meeting for ZGN-1061 Suspends IND filing plans for ZGN-1258 based on nonclinical [...]
Wright Medical Group N.V. Announces Termination of Contingent Value Rights Agreement
11/03/2019
AMSTERDAM, The Netherlands, March 11, 2019 (GLOBE NEWSWIRE) -- Wright Medical Group N.V. (NASDAQ:WMGI) today announced the expiration in accordance with its terms of the Contingent Value Rights Agreement dated as of [...]
Avid Bioservices Reports Financial Results for Third Quarter Fiscal 2019 and Recent Developments
11/03/2019
-- Achieved Revenue of $13.8 Million, an Increase of 102% Compared to Prior Year Quarter -- -- Signed Project Expansion Orders with Existing Customers Representing $23.8 Million -- -- Completed Process Validation [...]
Cytokinetics Announces Additional Results From COSMIC-HF to be Presented at ACC.19
11/03/2019
SOUTH SAN FRANCISCO, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from COSMIC-HF ( C hronic O ral S tudy of M yosin Activation to I ncrease [...]
ChromaDex to Present at the 31st Annual ROTH Conference
11/03/2019
LOS ANGELES, March 11, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, Chairman and Co-Founder, Frank Jaksch, and Chief Financial Officer, Kevin Farr, [...]
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
11/03/2019
WALTHAM Mass. and CRESTWOOD, Ky., March 11, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to [...]

Pages